Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Semaglutide 2.4 mg (Wegovy):A Turning Point for Obesity

25 Jun 2021

Description

Ahead of ADA 2021, Dr. Thomas Wadden discusses the significance of the Wegovy approval for chronic weight management and Novo Nordisk's plans to evaluate an oral version. 

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.